Jiangsu Recbio Technology , Ltd. EBIT

The latest EBIT for 2179.HK is $-1.1B as of June 2026. That compares with $-1.3B in the prior-year period — up 15.2% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Jiangsu Recbio Technology , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 2179.HK's EBIT moved from $-1.3B to $-1.1B — a 15.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Jiangsu Recbio Technology , Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 2179.HK currently prints $-1.1B for EBIT, while the sector average sits near $110B. That is roughly 101.0% below the sector mean. Large gaps often invite a closer look at Jiangsu Recbio Technology , Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $-1.1B for 2179.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting 2179.HK's EBIT ($-1.1B), review year-over-year change from $-1.3B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.